logo.jpg
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
October 30, 2023 06:41 ET | ImCheck Therapeutics SAS
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting          Marseille, France, October 30, 2023 – ImCheck...
logo.jpg
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
October 18, 2023 15:50 ET | ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
logo.jpg
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
October 15, 2023 18:05 ET | ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...
logo.jpg
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
March 14, 2023 17:30 ET | ImCheck Therapeutics SAS
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR          Marseille, France, March 14, 2023 – ImCheck Therapeutics...
logo.jpg
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
April 08, 2022 13:00 ET | ImCheck Therapeutics SAS
ImCheck Provides Updated ICT01 and Pembrolizumab Combination Datafrom the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022         Continued positive safety data across a range of ICT01 doses...
logo.jpg
ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 03, 2022 05:03 ET | ImCheck Therapeutics SAS
ImCheck Announces First Patients Dosedin Phase II of EVICTION Trial for ICT01          EVICTION trial proceeds to Phase IIa based on promising Phase I patient datafor ICT01 across a broad range of...
logo.jpg
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021
October 01, 2021 08:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021 Marseille, France, October 1, 2021 – ImCheck Therapeutics today...
logo.jpg
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 17, 2021 08:00 ET | ImCheck Therapeutics SAS
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021         First EVICTION data from checkpoint inhibitor-refractory solid tumor...
logo.jpg
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
September 13, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021 Marseille, France, September 13, 2021 – ImCheck Therapeutics today announced that it will present...
Judicate West Neutral Diana B. Kruze Helps Launch Mediation Program to Address Post-COVID Eviction Disputes
June 18, 2021 17:41 ET | Judicate West
SAN FRANCISCO, June 18, 2021 (GLOBE NEWSWIRE) -- Judicate West, one of California’s leading providers of private dispute resolution services, announces that neutral Diana B. Kruze is leading a...